SITC 2026 Keynote and Registration Press Release

By Thomas Martin posted 13 days ago
SITC Announces Keynote Speakers Dr. Ton Schumacher and Dr. Catherine J. Wu at its 41 st Annual Meeting The largest cancer immunotherapy conference featuring the latest research in immuno-oncology MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Ton Schumacher, PhD from the Netherlands Cancer Institute as the Keynote Speaker at its 41 st Annual Meeting and Pre-Conference Programs (SITC 2026) with his presentation “T Cell Recognition of Human Cancer: 'Cracking the Code' ”. SITC also hosts Catherine J. Wu, MD from the Dana-Farber Cancer ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Chemotherapy for Previously Untreated Hodgkin Lymphoma

By SITC Communications posted 03-23-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Teclistamab in Combination with Daratumumab Hyaluronidase-fihj for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 03-06-2026
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Durvalumab with FLOT for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

By SITC Communications posted 12-01-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab With Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer

By SITC Communications posted 11-24-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications

By SITC Communications posted 11-20-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous Cell Carcinoma

By SITC Communications posted 10-13-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Lurbinectedin in Combination with Atezolizumab or Atezolizumab and Hyaluronidase-tqjs for Extensive-Stage Small Cell Lung Cancer

By SITC Communications posted 10-03-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Pembrolizumab and Berahyaluronidase Alfa-pmph for Subcutaneous Injection

By SITC Communications posted 09-22-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Grants Accelerated Approval to Linvoseltamab-gcpt for Relapsed or Refractory Multiple Myeloma

By SITC Communications posted 07-03-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Neoadjuvant and Adjuvant Pembrolizumab for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma

By SITC Communications posted 06-13-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Retifanlimab-dlwr With Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal

By SITC Communications posted 05-16-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting

By Thomas Martin posted 05-13-2025
SITC Announces Keynote Speakers Dr. Jennifer Wargo and Dr. Ira Mellman at its 40th Anniversary Annual Meeting Celebrating 40 years of driving breakthroughs in cancer immunotherapy MILWAUKEE, WI – The Society for Immunotherapy of Cancer (SITC) is proud to announce Jennifer A. Wargo, MD, MMSc, from The University of Texas MD Anderson Cancer Center as the Keynote Speaker at its 40 th Anniversary Annual Meeting and Pre-Conference Programs (SITC 2025) with her presentation “Targeting the Microbiome to Promote Health and End Cancer.” SITC also hosts Ira Mellman, PhD, FAACR, ...
0 comments

Oncology News Burst from the FDA: FDA Approves Penpulimab-kcqx for Non-Keratinizing Nasopharyngeal Carcinoma

By SITC Communications posted 04-25-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments

Oncology News Burst from the FDA: FDA Approves Nivolumab with Ipilimumab for Unresectable or Metastatic Hepatocellular Carcinoma

By SITC Communications posted 04-14-2025
In cooperation with the Food and Drug Administration (FDA), and as a service to our members, SITC will periodically distribute information about newly approved therapies for cancer patients. This helps the FDA inform oncologists and professionals in oncology-related fields of recent approvals in a timely manner. Included in the email from the FDA will be a link to the product label, which will provide the relevant clinical information on the indication, contraindications, dosing, and safety. In sending this information, SITC does not endorse any product or therapy and does not take any position ...
0 comments